Jasper Therapeutics Inc. Common Stock (JSPR)
Stock · NASDAQ · Health Care
$0.479as of 10/16/2026
Price chart
Active signals
JSPR Signal Track Record
How signals performed across all stocks →What JSPR's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 35 | -11.0% | 34% | September 16, 2026 |
| Bollinger Band BreakdownActive now | 25 | -7.4% | 36% | September 15, 2026 |
| Bollinger Band Breakout | 17 | -10.9% | 29% | August 11, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +2.4% | 60% | December 23, 2024 |
| Any 20-session window (baseline) | -7.8% | 37% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About JSPR
Jasper Therapeutics, Inc., a clinical stage biotechnology company, focuses on the design and development of therapies to treat immune-mediated diseases. It is advancing a pipeline of medicines, including KP-104, a dual-complement inhibitor that has demonstrated positive outcomes in paroxysmal nocturnal hemoglobinuria (PNH) and is under evaluation in other unmet need nephrology disorders; Briquilimab is an anti-KIT an…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 22
- Website
- jaspertx.com/
Fundamentals
- 1-day range
- $0.4755$0.5438
- Market cap
- $18.10M
- P/E (trailing)
- —
- P/E (forward)
- -0.41
- EPS (trailing)
- $-1.58
- Dividend yield
- —
- Beta
- 3.37
- Avg. volume
- 1.04M
Forecasts
1 analyst ratings
Jasper Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- JSPRJasper Therapeutics Inc. Common Stock$0.48▼ 9.77%Market cap $18.10MP/E —$0.3151$2.69
- PLURPluri Inc. Common Stock$0.93▼ 1.06%Market cap $19.53MP/E —$0.9$4.87
- PASGPassage Bio Inc. Common Stock$3.5▼ 2.78%Market cap $14.11MP/E —$3.29$20
- GRMLGreenland Mines Ltd. Common Stock$6▼ 13.79%Market cap $22.19MP/E —$2.82$27.48
- INTSIntensity Therapeutics Inc. Common stock$3.35▼ 0.89%Market cap $11.49MP/E —$3.1$43.5
- EVAXEvaxion A/S American Depositary Share$2.83▲ 1.07%Market cap $24.98MP/E —$2.72$12.15
- SNTISenti Biosciences Holdings Inc. Common Stock$0.225▼ 14.12%Market cap $11.18MP/E —$0.2399$2.88
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| JSPR Jasper Therapeutics Inc. Common Stock | $18.10M | — | $0.48 | ▼ 9.77% | $0.3151$2.69 |
| PLUR Pluri Inc. Common Stock | $19.53M | — | $0.93 | ▼ 1.06% | $0.9$4.87 |
| PASG Passage Bio Inc. Common Stock | $14.11M | — | $3.5 | ▼ 2.78% | $3.29$20 |
| GRML Greenland Mines Ltd. Common Stock | $22.19M | — | $6 | ▼ 13.79% | $2.82$27.48 |
| INTS Intensity Therapeutics Inc. Common stock | $11.49M | — | $3.35 | ▼ 0.89% | $3.1$43.5 |
| EVAX Evaxion A/S American Depositary Share | $24.98M | — | $2.83 | ▲ 1.07% | $2.72$12.15 |
| SNTI Senti Biosciences Holdings Inc. Common Stock | $11.18M | — | $0.225 | ▼ 14.12% | $0.2399$2.88 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Jasper Therapeutics Announces Completion Of 18-Patient Enrollment In Phase 2 IgA Nephropathy Cohort Of Vensobafusp Alfa; Initial Data Expected By Year-Endbenzinga · 10/15/2026
- Jasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding WarrantsYahoo · 10/7/2026
- Jasper Therapeutics Appoints Jeet Mahal As Interim Principal Financial Officer Effective October 9, 2026; Herb Cross Resigns As CFO Effective October 9, 2026Benzinga · 9/28/2026
- Jasper Therapeutics Announces Key Regulatory and Clinical AppointmentsYahoo · 9/15/2026
Insider Activity
Insider Actions →- EMSTER KURT VON · July 31, 2026 · Grant7.5K
- Thomas G. Wiggans · July 31, 2026 · Grant7.5K
- Judith Anne Shizuru · July 31, 2026 · Grant7.5K
- Svetlana Lucas · July 31, 2026 · Grant7.5K
- Crutcher Patrick J · July 31, 2026 · Grant7.5K
- Ros Matthew E · July 20, 2026 · Buy881
- Crutcher Patrick J · July 20, 2026 · Buy888
- Crutcher Patrick J · July 16, 2026 · Grant15.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 15.81M
- Total value held
- $13.84M
- Institutional holders
- 56
- Unknown2.67M
- Unknown1.62M
- Unknown1.41M
- Unknown1.35M
- Unknown1.33M
- Unknown1.17M
- Unknown1.10M
- Unknown1.07M
- Unknown582.8K
- Unknown465.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Jasper Therapeutics Names Interim CFO
Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.
Jasper Therapeutics Names Interim CFO. Jasper Therapeutics announced that Herb Cross will resign as Chief Financial Officer effective October 9, 2026. Jeet Mahal has been appointed as the interim Principal Financial Officer to take over the role. This leadership change occurs while the stock trades well below its 52-week high and near recent support levels.